Billiontoone (NASDAQ:BLLN) Insider Bosch John Roderick Ten Sells 2,832 Shares

Billiontoone, Inc. (NASDAQ:BLLN) insider Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock in a transaction on Monday, June 15th. The shares were sold at an average price of $101.47, for a total value of $287,363.04. Following the sale, the insider directly owned 34,968 shares of the company’s stock, valued at approximately $3,548,202.96. The trade was a 7.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Price Performance

BLLN opened at $99.38 on Thursday. The stock has a market cap of $4.57 billion and a price-to-earnings ratio of 180.69. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $138.70. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The stock has a fifty day moving average price of $89.23 and a 200 day moving average price of $87.40.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The firm had revenue of $108.39 million for the quarter, compared to analyst estimates of $95.81 million. Billiontoone’s revenue for the quarter was up 83.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.39) EPS. Analysts forecast that Billiontoone, Inc. will post 0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on BLLN shares. Weiss Ratings cut Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 5th. JPMorgan Chase & Co. boosted their price target on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Guggenheim boosted their price target on Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Wells Fargo & Company reduced their price target on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research report on Thursday, March 5th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $125.29.

Hedge Funds Weigh In On Billiontoone

A number of institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC increased its stake in shares of Billiontoone by 26.1% in the first quarter. Perceptive Advisors LLC now owns 91,812 shares of the company’s stock worth $7,248,000 after purchasing an additional 19,000 shares during the period. Bank of America Corp DE increased its stake in shares of Billiontoone by 8,603.4% in the first quarter. Bank of America Corp DE now owns 12,707 shares of the company’s stock worth $1,003,000 after purchasing an additional 12,561 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Billiontoone by 151.8% in the first quarter. The Manufacturers Life Insurance Company now owns 30,506 shares of the company’s stock worth $2,408,000 after purchasing an additional 18,389 shares during the period. Renaissance Technologies LLC bought a new position in shares of Billiontoone in the first quarter worth about $4,046,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Billiontoone in the first quarter worth about $1,539,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.